Comparative Pharmacology
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus NIZORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GYNE LOTRIMIN 3 versus NIZORAL.
GYNE-LOTRIMIN 3 vs NIZORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
Inhibits fungal CYP51 (lanosterol 14α-demethylase), blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Intravaginal: one applicatorful (5 g of 2% cream) or one suppository (200 mg) once daily at bedtime for 3 days.
Ketoconazole 200 mg orally once daily with food. For severe infections, increase to 400 mg once daily. Duration depends on indication.
None Documented
None Documented
Terminal elimination half-life is 3.5–5 hours for topical administration; systemic absorption is minimal (<0.5%), so half-life reflects local clearance.
Biphasic elimination: initial half-life ~2 hours, terminal half-life 6–10 hours in adults with normal hepatic function; prolonged in hepatic impairment.
Clotrimazole is primarily excreted via feces (biliary elimination) as metabolites, with approximately 0.5% excreted renally as unchanged drug.
Approximately 70% of the dose is excreted unchanged in feces via biliary elimination, and about 20–35% is excreted in urine, with less than 1% as unchanged drug in urine.
Category C
Category C
Azole Antifungal
Azole Antifungal